{"id":3228,"date":"2023-04-11T21:10:35","date_gmt":"2023-04-12T02:10:35","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=3228"},"modified":"2023-04-11T21:10:38","modified_gmt":"2023-04-12T02:10:38","slug":"association-of-treatment-with-nirmatrelvir-and-the-risk-of-post-covid-19-condition","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/04\/11\/association-of-treatment-with-nirmatrelvir-and-the-risk-of-post-covid-19-condition\/","title":{"rendered":"Association of Treatment With Nirmatrelvir and the Risk of Post\u2013COVID-19 Condition"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2802878\">JAMA<\/a><\/p>\n\n\n\n<p><strong>Key Points<\/strong><\/p>\n\n\n\n<p><strong>Question<\/strong>&nbsp;&nbsp;Is treatment with nirmatrelvir in the acute phase of SARS-CoV-2 infection associated with a lower risk of post\u2013COVID-19 condition (PCC)?<\/p>\n\n\n\n<p><strong>Findings<\/strong>&nbsp;&nbsp;In this cohort study of 281\u202f793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe COVID-19 illness, compared with 246\u202f076 who had no treatment, nirmatrelvir use in the acute phase (n\u2009=\u200935\u202f717) was associated with reduced risk of PCC, including reduced risk of 10 of 13 post\u2013acute sequelae in various organ systems, as well as reduced risk of post\u2013acute death and post\u2013acute hospitalization. Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection.<\/p>\n\n\n\n<p><strong>Meaning<\/strong>&nbsp;&nbsp;In people with SARS-CoV-2 infection and at least 1 risk factor for progression to severe COVID-19 illness, treatment with nirmatrelvir during the acute phase of COVID-19 was associated with reduced risk of PCC.<\/p>\n<a rel=\"nofollow\" href=\"\/secure-location.php\" style=\"display: none;\" title=\"t XDrJQ\"><\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>JAMA Key Points Question&nbsp;&nbsp;Is treatment with nirmatrelvir in the acute phase of SARS-CoV-2 infection associated with a lower risk of post\u2013COVID-19 condition (PCC)? Findings&nbsp;&nbsp;In this cohort study of 281\u202f793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe COVID-19 illness, compared with 246\u202f076 who had no treatment, nirmatrelvir use [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":false,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[35,14],"tags":[],"class_list":["post-3228","post","type-post","status-publish","format-standard","hentry","category-covid-therapies","category-science-and-tech"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=3228"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3228\/revisions"}],"predecessor-version":[{"id":3229,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3228\/revisions\/3229"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=3228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=3228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=3228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}